If Amarin investors' new plan is to ask companies on conference calls whether they have an interest in a making a deal, bravo. Amarin shares traded up nearly 10% intraday on the surprise disclosure during a shareholder call for Elan discussing other proposed purchases.
In this video, health-care analyst David Williamson discusses what this and the recent buyout of a competitor means for Amarin investors and what key catalyst is coming for the company before 2013 comes to a close.
